logo-loader

Open Orphan PLC targeting Q3 for profitability as it expands range of pharma and COVID-19 services

Published: 13:15 25 Jun 2020 BST

Proactive Research analyst Emma Ulker says Open Orphan PLC's (LON:ORPH) full year 2019 results reflect a period of transition, as the company consolidated only six months of Venn revenues, with the focus being on integration and ongoing streamlining of the business, following the post–period acquisition of hVIVO in January.

Ulker says the outlook includes expanding its range of pharma services and completing the development of a COVID-19 HVC model which is already attracting the attention of the global pharma industry.

Click here to read Emma Ulker's latest update Open Orphan: Focused on a buoyant outlook

hVIVO chairman Cathal Friel says he remains committed to hVIVO following...

hVIVO PLC (AIM:HVO) chairman Cathal Friel joined Proactive's Stephen Gunnion to discuss the sale of shares in hVIVO PLC by directors, including himself. Friel explained his decision to sell a portion of his shares in hVIVO was to accommodate the high demand from major institutions while...

1 month ago